GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » Goodwill

BDTX (Black Diamond Therapeutics) Goodwill : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Black Diamond Therapeutics's goodwill for the quarter that ended in Dec. 2024 was $0.00 Mil.


Black Diamond Therapeutics Goodwill Historical Data

The historical data trend for Black Diamond Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics Goodwill Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill
Get a 7-Day Free Trial - - - - -

Black Diamond Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Black Diamond Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Black Diamond Therapeutics  (NAS:BDTX) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Black Diamond Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (A: Dec. 2024 )=Goodwill/Total Assets
=0/122.64
=

Black Diamond Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (Q: Dec. 2024 )=Goodwill/Total Assets
=0/122.64
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Black Diamond Therapeutics Goodwill Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Black Diamond Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Main Street, 14th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Executives
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Ra Capital Nexus Fund, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani director, 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein director, officer: See Remarks OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov officer: CHIEF MEDICAL OFFICER C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck officer: CHIEF SCIENTIFIC OFFICER C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni officer: SEE REMARKS C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon director
Mark A. Velleca director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709